A database containing the names 
  of the babies born in Ontario between 1917 and 2018. 
  Counts of fewer than 5 names were suppressed for privacy.

Provides a wrapper for the Onboard Data building data API <https://api.onboarddata.io/swagger>. Along with streamlining access to the API, this package simplifies access to sensor time series data, metadata (sensors, equipment, and buildings), and details about the Onboard data model/ontology.

Automated reporting in Word and PowerPoint can require customization for each organizational template. This package works around this by adding standard reporting functions and an abstraction layer to facilitate automated reporting workflows that can be replicated across different organizational templates.

Allows users to discover and retrieve Ocean Networks Canada's oceanographic data in raw, text, image, audio, video or any other format available. Provides a class that wraps web service calls and business logic so that users can download data with a single line of code.

Allows you to easily execute expensive compute operations only once, and save the resulting object to disk.

Medication adherence, defined as medication-taking behavior that aligns with the agreed-upon 
    treatment protocol, is critical for realizing the benefits of prescription medications. 
    Medication adherence can be assessed using electronic adherence monitoring devices (EAMDs), 
    pill bottles or boxes that contain a computer chip that records the date and time of each 
    opening (or “actuation”). Before researchers can use EAMD data, they must apply a series of 
    decision rules to transform actuation data into adherence data. 
    The purpose of this R package ('oncmap') is to transform EAMD actuations in the form of a raw .csv file, 
    information about the patient, regimen, and non-monitored periods into two daily adherence values -- 
    Dose Taken and Correct Dose Taken.

Bayesian logistic regression model with optional
  EXchangeability-NonEXchangeability parameter modelling for flexible
  borrowing from historical or concurrent data-sources. The safety model
  can guide dose-escalation decisions for adaptive oncology Phase I
  dose-escalation trials which involve an arbitrary number of
  drugs. Please refer to Neuenschwander et al. (2008)
  <doi:10.1002/sim.3230> and Neuenschwander et al. (2016)
  <doi:10.1080/19466315.2016.1174149> for details on the methodology.